The majority of the patients achieved an overall response and/or clinical benefit in a phase 1 trial evaluating ovarian epithelial cancer (100%), HER2-positive sarcoma (67%), EGFR-positive biliary tract cancer (65%), advanced gastric/pancreatic cancer (82%), hepatocellular carcinoma (67%), and colorectal cancer (70%). This evidence concerns the gene ERBB2 and ovarian carcinoma.